GOSS Gossamer Bio Inc.

12.15
+0.05  (+0%)
Previous Close 12.1
Open 12.16
Price To Book 3.01
Market Cap 920,877,684
Shares 75,792,402
Volume 939,816
Short Ratio
Av. Daily Volume 630,649
Stock charts supplied by TradingView

NewsSee all news

  1. Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific Program

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  2. Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients

    SAN FRANCISCO and CINCINNATI, May 27, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been

  3. Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients

    SAN FRANCISCO and CINCINNATI, May 27, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been

  4. Gossamer Bio Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  5. Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to commence 2H 2020.
AKB-4924 (GB004)
Ulcerative Colitis
Phase 1b data due 2H 2020.
GB002
Pulmonary arterial hypertension (PAH)
Phase 2 data due 2H 2020.
GB001
Nasal polyps / Chronic spontaneous urticaria
Phase 2b top-line data 2H 2020.
GB001
Eosinophilic asthma
Phase 1/2 further data due 2H 2020.
GB1275
Solid tumors

Latest News

  1. Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific Program

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  2. Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients

    SAN FRANCISCO and CINCINNATI, May 27, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been

  3. Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients

    SAN FRANCISCO and CINCINNATI, May 27, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been

  4. Gossamer Bio Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  5. Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  6. Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)

    CINCINNATI, May 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic

  7. Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update

    - GB001 interim analysis of LEDA trial in moderate-to-severe eosinophilic asthma completed - - GB001 intellectual property estate strengthened with issuance of new patent by USPTO covering lysine salt drug substance

  8. Gossamer Bio to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 12, 2020

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  9. Gossamer Bio Investigated by Block & Leviton; Investors Who Have Lost Money Should Contact the Firm

    BOSTON, March 25, 2020 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, announces that it has opened an investigation into Gossamer Bio, Inc. (NASDAQ:GOSS) and

  10. Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

    – Clinical trial results for all four clinical-stage product candidates in target areas of immunology, inflammation and oncology expected in 2020 – – Cash, cash equivalents and marketable securities totaled $401.8

  11. Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 2021 Conference Call and Webcast Today, March 16, 2020 at 8:30 a.m. EST

  12. Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020

    CINCINNATI, March 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic

  13. Gossamer Bio Announces Participation in 9th Annual SVB Leerink Global Healthcare Conference

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  14. Gossamer Bio Announces Data Presentations at the Congress of the European Crohn's and Colitis Organisation

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  15. Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension

    Data presented at the 9th Annual Glaucoma 360 New Horizons Forum Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and

  16. Gossamer Bio Announces Data Presentation at the 2020 Crohn's & Colitis Congress

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  17. Topical Ocular Formulation of Aerpio Pharmaceutical's AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial

    Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth

  18. Gossamer Bio Announces Participation in Upcoming Investor Conferences

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  19. Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  20. Gossamer Bio Announces Third Quarter 2019 Financial Results

    – Clinical programs on track for multiple topline data releases in 2020 – – Entered clinical trial collaboration with Merck to evaluate KEYTRUDA® (pembrolizumab) in combination with GB1275 in advanced solid tumors

  21. Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors

    – Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – – GB1275 granted Orphan Drug Designation for the treatment of pancreatic cancer by the U.S. Food and Drug Administration – –

  22. Gossamer Bio Announces Data Presentations at the American Heart Association Scientific Sessions 2019

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  23. Gossamer Bio Announces Data Presentations at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2019

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  24. Gossamer Bio Announces Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting

    - First-in-human Phase 1/2 trial of GB1275 to be featured in trial-in-progress poster - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and

  25. Aerpio Reports Third Quarter 2019 Financial Results and Provides Business Update

    Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the

  26. Gossamer Bio to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 12, 2019

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  27. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

  28. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

  29. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

  30. Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

    Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of

  31. Gossamer Bio Announces Participation in the 2019 Cantor Global Healthcare Conference

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,

  32. Gossamer Bio Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology,